Psychiatry & Neurology, Clinical Neurophysiology · Boerne, TX
NPI
1740286764
Since 2005
Specialty
Psychiatry & Neurology, Clinical Neurophysiology
Code 2084N0600X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1580 S Main St Ste 201
Boerne, TX, 78006
Phone (210) 692-1245
Groups this clinician bills Medicare through
Medicare paid, 2024
$306K
7,465 services
Medicare patients, 2024
131
Average age 66
Drug cost, 2024
$2.3M
771 prescriptions
Company payments, 2025
$791
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Suzanne K Gazda was code 96366 (intravenous infusion, hydration), 261 times for 13 patients. In total Suzanne K Gazda billed 7,465 services in 28 codes, and Medicare paid $306K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 96366 Intravenous Infusion, Hydration | Office | 261 | 13 | $11.84 | $3,091 |
| 99214 Office E&M - Established | Office | 123 | 76 | $76.59 | $9,421 |
| 99213 Office E&M - Established | Office | 91 | 73 | $60.30 | $5,487 |
| 96365 Intravenous Infusion, Hydration | Office | 87 | 17 | $38.90 | $3,384 |
| 99215 Office E&M - Established | Office | 35 | 26 | $110.72 | $3,875 |
By year: 2022 $224K for 6,699 services; 2023 $281K for 6,067 services; 2024 $306K for 7,465 services.
Medicare prescription drug claims, 2024
In 2024, the drug Suzanne K Gazda prescribed most often to Medicare patients was Gabapentin, with 75 prescriptions and refills. In total Suzanne K Gazda wrote 771 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 75 | 101 | 18 | $1,580 |
| Sodium Chloride 0.9 % Sodium Chloride | 50 | 50 | Under 11 | $305 |
| Baclofen Generic | 37 | 77 | 13 | $988 |
| Glatopa Glatiramer Acetate | 36 | 36 | Under 11 | $143K |
| Teriflunomide Generic | 33 | 35 | Under 11 | $49K |
| Glatiramer Acetate Generic | 30 | 37 | Under 11 | $102K |
| Dalfampridine Er Dalfampridine | 29 | 37 | Under 11 | $26K |
| Kesimpta Pen Ofatumumab | 28 | 28 | Under 11 | $242K |
| Citalopram Hbr Citalopram Hydrobromide | 26 | 49 | Under 11 | $105 |
| Donepezil Hcl Generic | 25 | 39 | Under 11 | $158 |
| Tizanidine Hcl Generic | 23 | 32 | Under 11 | $340 |
| Diphenhydramine Hcl Generic | 21 | 21 | Under 11 | $71.89 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 21 | 21 | Under 11 | $495K |
| Ondansetron Hcl Ondansetron Hcl/Pf | 18 | 18 | Under 11 | $54.3 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 17 | 17 | Under 11 | $489K |
Brand drugs: 221 claims; generic drugs: 550 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Suzanne K Gazda $791 ($791 in general payments such as food, travel and fees) from 13 companies. The largest payer was Novartis Pharmaceuticals Corporation with $301.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 21 | $301 |
| Octapharma USA, Inc. | 4 | $77.94 |
| Ge Healthcare GEHC | 3 | $71.18 |
| Grifols USA, LLC | 3 | $61.4 |
| Abbvie Inc. ABBV | 3 | $60.06 |
| TG Therapeutics, Inc. TGTX | 3 | $53.86 |
| Axsome Therapeutics, Inc. AXSM | 1 | $33.99 |
| Argenx US, Inc. ARGX | 1 | $29.2 |
| Xeris Pharmaceuticals, Inc. | 1 | $24.22 |
| Pfizer Inc. PFE | 1 | $22.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.